{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-285572","form_type":"8-K/A","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-06-26T20:31:01+00:00","discovered_at":"2026-06-26T20:32:00.520601+00:00","generated_at":"2026-06-26T20:32:43.011970+00:00","sec_items":["3.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Quince Therapeutics announces 1-for-20 reverse stock split effective June 29, 2026","bullets":["Reverse stock split ratio set at 1-for-20, approved by board after stockholder authorization.","Certificate of Amendment filed with Delaware; effective 11:59 pm ET June 29.","Shares trade split-adjusted on Nasdaq starting June 30; new CUSIP 22053A305.","Outstanding shares reduce from ~19.56M to ~0.98M; fractional shares rounded up.","All options and warrants proportionally adjusted; Equiniti Trust acts as exchange agent."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-285572","json":"https://secwatch.observer/filing/0001193125-26-285572.json","markdown":"https://secwatch.observer/filing/0001193125-26-285572.md","text":"https://secwatch.observer/filing/0001193125-26-285572.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526285572/0001193125-26-285572-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526285572/d30985d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T20:32:43.011970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}